

## Pathology/Laboratory and Molecular Pathology/MAAA/GSP CPT Code Change Applications February 2020 CPT® Editorial Panel Meeting

Pathology/Laboratory and Molecular Pathology/MAAA/GSP CPT Code Change Applications (CCAs) that have been submitted for consideration by the CPT Editorial Panel at its February 2020 meeting are listed below. These applications will be included in the proposed Panel agenda that will be posted to the AMA website on December 6, 2019. This listing includes the code application names, code(s) affected, and a description of the request. **Until such time as the CPT Editorial Panel acts on these requests, the following information is provided for informational purposes only, giving interested individuals the information to help determine whether or not to attend the meeting and provide comment on a given topic(s).**

This listing of Pathology/Laboratory and Molecular Pathology/MAAA/GSP applications is being posted ahead of the full September Panel meeting agenda in order to provide the Molecular Pathology Advisory Group (MPAG) and the Pathology Coding Caucus (PCC) sufficient time to review comments from interested stakeholders prior to making their recommendations to the CPT Editorial Panel.

Codes that contain an 'X' (e.g., 10X24, 23X42, 03X01T) below are temporary codes that are intended to give readers an idea of the proposed placement in the code set of the potential code changes. **These temporary codes are not used for claims reporting and will be removed and not retained when the final CPT Datafiles are distributed on August 31<sup>st</sup> of each year. To report the services described by the "X" codes listed on this form, please refer to the actual codes as they appear in the CPT Datafiles publication distributed on August 31<sup>st</sup> of the corresponding year.**

Upon review of these applications, if the reviewer believes that they will need to provide comment on an issue, they should send a request for a copy of the application and associated materials to [Michael Pellegrino](#). This request for review of the agenda materials should contain the identity of the interested party seeking such and a brief summary of the basis for the request (e.g., associated vendor/ industry representative).

Any interested parties wishing to provide written comments on any agenda items should be aware of the following relevant deadlines for provision of written comments on the agenda to ensure comment review by all parties. Additional verbal comments on any issue can be provided in person at the Panel meeting following a statement of conflict of interest. The applicant(s) who submitted the original code change application is automatically considered an interested party and is notified by AMA staff of any request for review submitted by another party.

\*Interested party requests will not be processed until the interested party submits a signed confidentiality agreement and disclosure of interest form.

Updated November 18, 2019

- New
- ▲ Revision
- + Add on
- D Deletion



Please follow the instructions in the correspondence that accompanies the materials.

Pathology/Laboratory and Molecular Pathology, Multianalyte Assays with Algorithmic Analyses, and Genomic Sequencing Procedures Deadlines for Interested Stakeholders	
<b>Request for Code Change Application Materials</b>	<b>November 29, 2019</b>
<b>Submission of Written Comments</b>	<b>December 4, 2019</b>

During the time between now and the Panel meeting, this listing of Pathology/Laboratory and Molecular Pathology/MAAA/GSP CCAs may be modified to reflect changes – additions, deletions or updates. Please check back frequently for the most up to date information. Outcomes on these actions will be listed in the CPT Editorial Panel Summary of Actions for the February 2020 meeting, which will be published on or before March 11, 2020 to the CPT home page of the AMA website <http://www.ama-assn.org/go/panel-actions>.

Tab #	Name	Code #	Request-Description
6	Red Blood Cell Exchange - Automated and Manual	<ul style="list-style-type: none"> <li>● 3XX00</li> <li>● 3XX01</li> </ul>	Add codes 3XX00 and 3XX01 to allow separate reporting for automated red blood cell exchange versus manual red blood cell exchange
10	Acetaminophen Therapeutic Drug Assay	<ul style="list-style-type: none"> <li>● 80XXX</li> </ul>	Add code 80XXX to report acetaminophen TDA and revise TDA guidelines to add testing for a suspected non-prescribed medication

Updated November 18, 2019

- New
- ▲ Revision
- + Add on
- D Deletion

Tab #	Name	Code #	Request-Description
11	Alcohol (Ethanol) Immunoassay	● 81XX3	Add code 81XX3 for reporting immunoassay and enzymatic methods of testing for alcohol (ethanol) in specimens other than urine and breath.
12	Amiodarone Therapeutic Drug Assay	● 80XX2	Add code to identify therapeutic drug assay/monitoring for Amiodarone
13	Salicylate Therapeutic Drug Assay	● 80XX1	Add code 80XX1 to report salicylate TDA and 2) to revise TDA guidelines to add testing for a suspected non-prescribed medication
14	Bacterial Vaginosis	● 815X9	Add a Category I Multianalyte Assay with Algorithmic Analysis (MAAA) code (81XX4) for bacterial vaginosis, quantitative real-time amplification of RNA markers for Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species, utilizing vaginal fluid specimens.
15	Tier 1-BCAT1 IKZF1	● 81XX0	Add code 81XX0 for reporting quantitative or qualitative promoter methylation analysis of the BCAT1 and IKZF1 genes in colorectal cancer tissues.
16	GSP-Copy Number Variation Analysis	● 81XX5	Add a genomic sequencing procedure code for detecting copy number variation throughout the genome
17	GSP-Epilepsy	● 81XX6	Add a genomic sequencing procedure for reporting for epilepsy gene panel
18	MAAA Idiopathic Pulmonary Fibrosis	● 81XX1	Add code 81XX1 for reporting MAAA test for suspected idiopathic pulmonary fibrosis

Updated November 18, 2019

● New  
▲ Revision  
+ Add on  
D Deletion

Tab #	Name	Code #	Request-Description
19	MAAA Gene Sequencing Classifier Assay	● 81XX2	Add code 81XX2 for reporting genomic sequencing classifier
20	MAAA Liver Fibrosis	● 81XX3	Add code 81XX3 to identify multianalyte assay with algorithmic analysis for liver fibrosis testing.
21	Admin MAAA Adrenal Cortical Carcinoma	● 001XM	Add an Administrative Multianalyte Assay with Algorithmic Analysis (MAAA) code 001XM for adrenal cortical carcinoma, biochemical assay of 25 steroid markers for utilizing urine.